HEIDELBERG, Germany--(BUSINESS WIRE)--mtm laboratories today announced the launch of the CE-labelled Cervatec™ Assay and, at the same time, the results from a large prospective study demonstrating substantially superior sensitivity to the presence of disease over Pap test alone. The Cervatec™ ELISA assay will initially be commercialized in Central Europe as an adjunct to the Pap Test in screening of women aged 35 and younger.
